Trademark: 87677145
Word
BECAFRI
Status
Dead
Status Code
606
Status Date
Monday, February 14, 2022
Serial Number
87677145
Mark Type
4000
Filing Date
Wednesday, November 8, 2017
Published for Opposition
Tuesday, November 13, 2018
Abandoned Date
Monday, February 14, 2022

Trademark Owner History

Classifications
5 Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Events
Feb 14, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Feb 14, 2022
Abandonment - No Use Statement Filed
Jul 14, 2021
Notice Of Approval Of Extension Request E-Mailed
Jul 13, 2021
Sou Extension 5 Granted
Jul 6, 2021
Sou Extension 5 Filed
Jul 13, 2021
Case Assigned To Intent To Use Paralegal
Jul 6, 2021
Sou Teas Extension Received
Jan 6, 2021
Notice Of Approval Of Extension Request E-Mailed
Jan 4, 2021
Sou Extension 4 Granted
Jan 4, 2021
Sou Extension 4 Filed
Jan 4, 2021
Sou Teas Extension Received
Jun 16, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 12, 2020
Sou Extension 3 Granted
Jun 12, 2020
Sou Extension 3 Filed
Jun 12, 2020
Sou Teas Extension Received
Dec 24, 2019
Notice Of Approval Of Extension Request E-Mailed
Dec 20, 2019
Sou Extension 2 Granted
Dec 20, 2019
Sou Extension 2 Filed
Dec 20, 2019
Sou Teas Extension Received
Jun 11, 2019
Notice Of Approval Of Extension Request E-Mailed
Jun 7, 2019
Sou Extension 1 Granted
Jun 7, 2019
Sou Extension 1 Filed
Jun 7, 2019
Sou Teas Extension Received
Jan 8, 2019
Noa E-Mailed - Sou Required From Applicant
Nov 13, 2018
Official Gazette Publication Confirmation E-Mailed
Nov 13, 2018
Published For Opposition
Oct 24, 2018
Notification Of Notice Of Publication E-Mailed
Oct 5, 2018
Law Office Publication Review Completed
Oct 2, 2018
Approved For Pub - Principal Register
Aug 31, 2018
Teas/Email Correspondence Entered
Aug 31, 2018
Correspondence Received In Law Office
Aug 29, 2018
Assigned To Lie
Aug 13, 2018
Teas Response To Office Action Received
Feb 27, 2018
Notification Of Non-Final Action E-Mailed
Feb 27, 2018
Non-Final Action E-Mailed
Feb 27, 2018
Non-Final Action Written
Feb 20, 2018
Assigned To Examiner
Nov 19, 2017
New Application Office Supplied Data Entered
Nov 11, 2017
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24